Advertisement

Clinical use of CSF neopterin levels in CNS demyelinating diseases

Published:August 18, 2022DOI:https://doi.org/10.1016/j.jns.2022.120385

      Highlights

      • This study evaluated CSF neopterin in patients with CNS demyelinating diseases.
      • CSF neopterin levels were significantly higher in AQP4-IgG-positive NMOSD than MS.
      • CSF neopterin levels tended to be higher in MOGAD compared with MS.
      • CSF neopterin accurately discriminated active and inactive phases of the disease.

      Abstract

      Background

      There is some phenotypic overlap between MS, AQP4-IgG positive NMOSD, and MOG-IgG associated disease (MOGAD), and distinguishing a true relapse and a pseudorelapse can be difficult. CSF neopterin, a marker of inflammation-immune-mediated processes in the CNS, may be a useful marker in a wide range of CNS infectious and inflammatory diseases. We compared CSF neopterin levels and other CSF parameters in patients with MS, AQP4-IgG-positive NMOSD, and MOGAD and also investigated whether CSF neopterin levels can distinguish between active and inactive phases of the diseases.

      Methods

      We retrospectively reviewed the medical records of 22 patients with MS, 18 with AQP4-IgG-positive NMOSD, and five with MOGAD. CSF neopterin concentrations were measured by HPLC with fluorometric detection.

      Results

      CSF neopterin levels at diagnosis were significantly higher in patients with AQP4-IgG-positive NMOSD (52.77 ± 34.56 pmol/mL) than patients with MS (16.92 ± 5.03 pmol/mL, p < 0.001), and tended to be higher in patients with MOGAD (28.87 ± 9.66 pmol/mL) than patients with MS (p = 0.092). ROC analysis revealed that CSF neopterin most accurately discriminated between MS and AQP4-IgG-positive NMOSD (AUC, 0.912; sensitivity, 75.0%; specificity, 100.0%). At diagnosis/relapse and during remission, CSF neopterin most accurately discriminated between the disease phases in patients with MS (AUC, 0.779; sensitivity, 58.1%; specificity, 94.7%) and patients with AQP4-IgG-positive NMOSD (AUC, 0.934; sensitivity, 83.3%; specificity, 94.1%).

      Conclusion

      Measurement of CSF neopterin may be useful for differential diagnosis and assessment of disease activity in CNS demyelinating diseases. Further studies with larger cohorts, including comparisons with other biomarkers, are needed to validate the utility of CSF neopterin.

      Keywords

      Abbreviations:

      AQP4 (aquaporin-4), CNS (central nervous system), CSF (cerebrospinal fluid), HPLC (high-performance liquid chromatography), MOG (myelin oligodendrocyte glycoprotein), MS (multiple sclerosis), NMOSD (neuromyelitis optica spectrum disorder), ROC (receiver operating characteristic.)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hamid S.H.M.
        • Whittam D.
        • Mutch K.
        • et al.
        What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
        J. Neurol. 2017; 264: 2088-2094https://doi.org/10.1007/s00415-017-8596-7
        • Cook L.J.
        • Rose J.W.
        • Alvey J.S.
        • et al.
        Collaborative international research in clinical and longitudinal experience study in NMOSD.
        Neurol. Neuroimmunol. Neuroinflamm. 2019; 6e583https://doi.org/10.1212/NXI.0000000000000583
        • Jurynczyk M.
        • Geraldes R.
        • Probert F.
        • et al.
        Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
        Brain. 2017; 140: 617-627https://doi.org/10.1093/brain/aww350
        • Juryńczyk M.
        • Tackley G.
        • Kong Y.
        • et al.
        Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 132-136https://doi.org/10.1136/jnnp-2016-314005
        • Robertson J.
        • Gostner J.M.
        • Nilsson S.
        • Andersson L.M.
        • Fuchs D.
        • Gisslen M.
        Serum neopterin levels in relation to mild and severe COVID-19.
        BMC Infect. Dis. 2020; 20: 1-6https://doi.org/10.1186/s12879-020-05671-7
        • Millner M.M.
        • Franthal W.
        • Thalhammer G.H.
        • et al.
        Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children.
        Clin. Chem. 1998; 44: 161-167https://doi.org/10.1093/clinchem/44.1.161
        • Hagberg L.
        • Dotevall L.
        • Norkrans G.
        • et al.
        Cerebrospinal fluid neopterin concentrations in central nervous system infection.
        J. Infect. Dis. 1993; 168: 1285-1288https://doi.org/10.1093/infdis/168.5.1285
        • Sato T.
        • Coler-Reilly A.
        • Utsunomiya A.
        • et al.
        CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.
        PLoS Negl. Trop. Dis. 2013; 7e2479https://doi.org/10.1371/journal.pntd.0002479
        • Molero-Luis M.
        • Casas-Alba D.
        • Orellana G.
        • et al.
        Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases.
        Sci. Rep. 2020; 10: 18291https://doi.org/10.1038/s41598-020-75500-z
        • Fredrikson S.
        • Eneroth P.
        • Link H.
        Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.
        Clin. Exp. Immunol. 1987; 67: 76-81
        • Ott M.
        • Demisch L.
        • Engelhardt W.
        • Fischer P.A.
        Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
        J. Neurol. 1993; 241: 108-114https://doi.org/10.1007/BF00869773
        • Rajda C.
        • Galla Z.
        • Polyák H.
        • et al.
        Cerebrospinal fluid neurofilament light chain is associated with kynurenine pathway metabolite changes in multiple sclerosis.
        Int. J. Mol. Sci. 2020; 21: 2665https://doi.org/10.3390/ijms21082665
        • Miyaue N.
        • Yabe H.
        • Yamanishi Y.
        • et al.
        Relapse of neuromyelitis optica with occipital neuralgia and elevated CSF neopterin.
        Neurol. Clin. Neurosci. 2020; 8: 209-211https://doi.org/10.1111/ncn3.12393
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/S1474-4422(17)30470-2
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189https://doi.org/10.1212/WNL.0000000000001729
        • López-Chiriboga A.S.
        • Majed M.
        • Fryer J.
        • et al.
        Association of Mog-IgG Serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders.
        JAMA Neurol. 2018; 75: 1355-1363https://doi.org/10.1001/jamaneurol.2018.1814
        • Fredrikson S.
        • Link H.
        • Eneroth P.
        CSF neopterin as marker of disease activity in multiple sclerosis.
        Acta Neurol. Scand. 1987; 75: 352-355https://doi.org/10.1111/j.1600-0404.1987.tb05458.x
        • Dobson R.
        • Topping J.
        • Davis A.
        • Thompson E.
        • Giovannoni G.
        Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.
        Acta Neurol. Scand. 2013; 128: 321-327https://doi.org/10.1111/ane.12119
        • Norgren N.
        • Rosengren L.
        • Stigbrand T.
        Elevated neurofilament levels in neurological diseases.
        Brain Res. 2003; 987: 25-31https://doi.org/10.1016/S0006-8993(03)03219-0
        • Martin S.J.
        • McGlasson S.
        • Hunt D.
        • Overell J.
        Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies.
        J. Neurol. Neurosurg. Psychiatry. 2019; 90: 1059-1067https://doi.org/10.1136/jnnp-2018-319190
        • Lotan I.
        • Benninger F.
        • Mendel R.
        • Hellmann M.A.
        • Steiner I.
        Does CSF pleocytosis have a predictive value for disease course in MS?.
        Neurol. Neuroimmunol. Neuroinflamm. 2019; 6e584https://doi.org/10.1212/NXI.0000000000000584
        • Zheng Y.
        • Cai M.T.
        • Yang F.
        • et al.
        IgG index revisited: diagnostic utility and prognostic value in multiple sclerosis.
        Front. Immunol. 2020; 11: 1799https://doi.org/10.3389/fimmu.2020.01799
        • Joseph F.G.
        • Hirst C.L.
        • Pickersgill T.P.
        • et al.
        CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.
        J. Neurol. Neurosurg. Psychiatry. 2009; 80: 292-296https://doi.org/10.1136/jnnp.2008.150896
        • Shaw C.E.
        • Dunbar P.R.
        • Macaulay H.A.
        • Neale T.J.
        Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.
        J. Neurol. 1995; 242: 53-58https://doi.org/10.1007/BF00887815
        • Jarius S.
        • Paul F.
        • Franciotta D.
        • et al.
        Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
        J. Neurol. Sci. 2011; 306: 82-90https://doi.org/10.1016/j.jns.2011.03.038
        • Dale R.C.
        • Brilot F.
        • Fagan E.
        • Earl J.
        Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation.
        Dev. Med. Child Neurol. 2009; 51: 317-323https://doi.org/10.1111/j.1469-8749.2008.03225.x
        • Akaishi T.
        • Takahashi T.
        • Misu T.
        • et al.
        Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.
        Neurology. 2021; 97: e1-e12https://doi.org/10.1212/WNL.0000000000012175
        • Stangel M.
        • Fredrikson S.
        • Meinl E.
        • et al.
        The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.
        Nat. Rev. Neurol. 2013; 9: 267-276https://doi.org/10.1038/nrneurol.2013.41
        • Ciotti J.R.
        • Eby N.S.
        • Wu G.F.
        • et al.
        Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
        Mult. Scler. Relat. Disord. 2020; 45102399https://doi.org/10.1016/j.msard.2020.102399
        • Kaneko K.
        • Sato D.K.
        • Nakashima I.
        • et al.
        CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 927-936https://doi.org/10.1136/jnnp-2018-317969
        • de Paula Martins R.
        • Ghisoni K.
        • Lim C.K.
        • Aguiar A.S.
        • Guillemin G.J.
        • Latini A.
        Neopterin preconditioning prevents inflammasome activation in mammalian astrocytes.
        Free Radic. Biol. Med. 2018; 115: 371-382https://doi.org/10.1016/j.freeradbiomed.2017.11.022
        • Hofer L.S.
        • Mariotto S.
        • Wurth S.
        • et al.
        Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases.
        Mult. Scler. J. Exp. Transl. Clin. 2019; 5https://doi.org/10.1177/2055217319848463
        • Kuhle J.
        • Kropshofer H.
        • Hearing D.A.
        • et al.
        Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
        Neurology. 2019; 92: e1007-e1015https://doi.org/10.1212/WNL.0000000000007032
        • Abdelhak A.
        • Huss A.
        • Kassubek J.
        • Tumani H.
        • M, Otto.
        Serum GFAP as a biomarker for disease severity in multiple sclerosis.
        Sci. Rep. 2018; 8: 14798https://doi.org/10.1038/s41598-018-33158-8
        • Schindler P.
        • Grittner U.
        • Oechtering J.
        • et al.
        Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
        J. Neuroinflammation. 2021; 18: 105https://doi.org/10.1186/s12974-021-02138-7
        • Kallaur A.P.
        • Oliveira S.R.
        • Colado Simão A.N.
        • et al.
        Cytokine profile in relapsing remitting multiple sclerosis patients and the association between progression and activity of the disease.
        Mol. Med. Rep. 2013; 7: 1010-1020https://doi.org/10.3892/mmr.2013.1256
        • Wang K.C.
        • Lee C.L.
        • Chen S.Y.
        • et al.
        Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
        J. Interf. Cytokine Res. 2013; 33: 58-64https://doi.org/10.1089/jir.2012.0040